Seroprevalence and Determinants of SARS-CoV-2 Antibodies Among Healthcare Workers in Dar es Salaam, Tanzania

Studies from the Sub-Saharan African (SSA) countries suggest an underestimate of SARS-CoV-2 infections during the pandemic. We investigated the seroprevalence and factors associated with anti-SARS CoV-2 seropositivity among healthcare workers (HCWs) in Dar es Salaam, Tanzania. We conducted a cross-sectional study in three tertiary hospitals in Dar es Salaam among randomly selected HCWs between October 2021 and March 2022. Demographic and SARS-CoV-2-related exposures were collected as well as blood for Immunoglobulin G (IgG) against SARS-CoV-2 nucleocapsid (IgG-N) or spike (IgG-S) proteins using WHO/FDA-pre-qualified SARS-CoV-2 ELISA test kits. Descriptive statistics were used to determine the SARS-CoV-2 antibody prevalence. Multivariable Modified Poisson regression was used to determine the association between HCWs characteristics and SARS-CoV-2 serologic status. Of the 394 participants [mean age (SD) of 37.9 (9.8) years] included, 327 (83%) had never been tested for COVID-19 before the study and 148 (37.6%) had received at least one dose vaccine against COVID-19 at enrolment. The overall seroprevalence of SARS-CoV-2 IgG (including IgG-N, IgG-S or both) was 90.9% (95% CI: 76.7–96.8%). HCWs who had at least one dose of vaccine against COVID-19 were 13% more likely to be seropositive than those who were not vaccinated (aPR = 1.13 (95% CI: 1.02–1.25; p = 0.023). HCWs who believed they had COVID-19 but never tested had 9% higher seroprevalence compared to those who believed they never had COVID-19 (aPR = 1.09; 95% CI: 1.03–1.16; p = 0.003). HCWs working in the laboratory, anesthesia and obstetrics and gynecology departments were more likely to have SARS-CoV-2 antibodies than HCWs from the emergency medicine department (EMD). The seroprevalence of anti-SARS-CoV-2 IgG among HCWs in this study was high despite low vaccine coverage in this population indicating high SARS-CoV-2 exposure among HCWs. Our work highlights the need for more effective infection control practices in healthcare settings in future pandemics like these, especially among HCWs at highest risk.

Authors

Institutions

Publication Details

Journal
COVID
Published
2026-11-18
DOI
https://doi.org/10.3390/covid6110205
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Seroprevalence and Determinants of SARS-CoV-2 Antibodies Among Healthcare Workers in Dar es Salaam, Tanzania

Erick Alexander Mboya, Grace Ambrose Shayo, Tumaini Joseph Nagu, Faraja Simon Chiwanga et al.
2 links
COVID
SARS-CoV-2 and COVID-19 Research
article

Seroprevalence and Determinants of SARS-CoV-2 Antibodies Among Healthcare Workers in Dar es Salaam, Tanzania

Erick Alexander Mboya, Grace Ambrose Shayo, Tumaini Joseph Nagu, Faraja Simon Chiwanga, Claudia Hawkins, Mangaro Mabusi, Said Aboud, Raphael Zozimus Sangeda, Davis Elias Amani, Sabina Ferdinand Mugusi, Joan Rugemalila, Ferdinand M Mugusi, Doreen Kamori, Muhammad Bakari, Upendo Nkwera
article en

Abstract

Studies from the Sub-Saharan African (SSA) countries suggest an underestimate of SARS-CoV-2 infections during the pandemic. We investigated the seroprevalence and factors associated with anti-SARS CoV-2 seropositivity among healthcare workers (HCWs) in Dar es Salaam, Tanzania. We conducted a cross-sectional study in three tertiary hospitals in Dar es Salaam among randomly selected HCWs between October 2021 and March 2022. Demographic and SARS-CoV-2-related exposures were collected as well as blood for Immunoglobulin G (IgG) against SARS-CoV-2 nucleocapsid (IgG-N) or spike (IgG-S) proteins using WHO/FDA-pre-qualified SARS-CoV-2 ELISA test kits. Descriptive statistics were used to determine the SARS-CoV-2 antibody prevalence. Multivariable Modified Poisson regression was used to determine the association between HCWs characteristics and SARS-CoV-2 serologic status. Of the 394 participants [mean age (SD) of 37.9 (9.8) years] included, 327 (83%) had never been tested for COVID-19 before the study and 148 (37.6%) had received at least one dose vaccine against COVID-19 at enrolment. The overall seroprevalence of SARS-CoV-2 IgG (including IgG-N, IgG-S or both) was 90.9% (95% CI: 76.7–96.8%). HCWs who had at least one dose of vaccine against COVID-19 were 13% more likely to be seropositive than those who were not vaccinated (aPR = 1.13 (95% CI: 1.02–1.25; p = 0.023). HCWs who believed they had COVID-19 but never tested had 9% higher seroprevalence compared to those who believed they never had COVID-19 (aPR = 1.09; 95% CI: 1.03–1.16; p = 0.003). HCWs working in the laboratory, anesthesia and obstetrics and gynecology departments were more likely to have SARS-CoV-2 antibodies than HCWs from the emergency medicine department (EMD). The seroprevalence of anti-SARS-CoV-2 IgG among HCWs in this study was high despite low vaccine coverage in this population indicating high SARS-CoV-2 exposure among HCWs. Our work highlights the need for more effective infection control practices in healthcare settings in future pandemics like these, especially among HCWs at highest risk.

COVIDVol. 6(11)
Northwestern University (US), Muhimbili University of Health and Allied Sciences (TZ), Muhimbili National Hospital (TZ), National Institute for Medical Research (TZ)
Northwestern University, Muhimbili University of Health and Allied Sciences, University of Health and Allied Sciences
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon